CanSino Biologics-B (09966.HK): JSKN027 IND application officially accepted by CDE.

Smart Finance APP news, Innovent Biologics (09966.HK) announced that the company has filed an Investigational New Drug (IND) application for the clinical trial of JSKN027, a dual-specificity antibody-drug conjugate (ADC) targeting programmed death ligand 1 (PD-L1) and vascular endothelial growth factor receptor 2 (VEGFR2) developed independently by the company. The application has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The company plans to conduct a Phase I clinical study of JSKN027 for the treatment of advanced solid tumors, aiming to evaluate its safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, preliminary anti-tumor activity, and determine the maximum tolerated dose and/or recommended Phase II dose in this patient population.